Cyp1a2 protects against reactive oxygen production in mouse liver microsomes

Free Radical Biology and Medicine

Volumn 36, Issue 5, 2004, Pages 605-617

  Shertzer, Howard G ^a   Clay, Corey D ^a   Genter, Mary Beth ^a   Schneider, Scott N ^a   Nebert, Daniel W ^a   Dalton, Timothy P ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

2,3,7,8 Tetrahydrodibenzo p dioxin; CYP1A1; CYP1A2; CYP2E1; Free radicals; Mouse liver; Oxidative stress; Reactive oxygen

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THIOBARBITURIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANISOTROPY; ARTICLE; CONTROLLED STUDY; KNOCKOUT MOUSE; LIPID PEROXIDATION; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; WILD TYPE;

EID: 1242338755     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2003.11.013     Document Type: Article

References (91)

1. Hébert C.D., Harris M.W., Elwell M.R., Birnbaum L.S. Relative toxicity and tumor-promoting ability of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 2,3,4,7,8-pentachlorodibenzofuran (PCDF), and 1,2,3,4,7,8- hexachlorodibenzofuran (HCDF) in hairless mice. Toxicol. Appl. Pharmacol. 102:1990;362-377.
2. Kafafi S.A., Afeefy H.Y., Ali A.H., Said H.K., Kafafi A.G. Binding of polychlorinated biphenyls to the aryl hydrocarbon receptor. Environ. Health Perspect. 101:1993;422-428.
3. Kerkvliet N.I., Baecher-Steppan L., Smith B.B., Youngberg J.A., Henderson M.C., Buhler D.R. Role of the Ah locus in suppression of cytotoxic T lymphocyte activity by halogenated aromatic hydrocarbons (PCBs and TCDD): structure-activity relationships and effects in C57Bl/6 mice congenic at the Ah locus. Fundam. Appl. Toxicol. 14:1990;532-541.
4. Morris D.L., Jeong H.G., Jordan S.D., Kaminski N.E., Holsapple M.P. Characterization of the effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin in B6C3F1 and DBA/2 mice following single and repeated exposures. Arch. Toxicol. 72:1998;157-168.
5. Nebert D.W. The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects. CRC Crit. Rev. Toxicol. 20:1989;153-174.
6. Nebert D.W., Puga A., Vasiliou V. Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction. Ann. N.Y. Acad. Sci. 685:1993;624-640.
7. Van den B.M., Birnbaum L.S., Bosveld A.T.C., Brunstrom B., Cook P., Feeley M., Giesy J.P., Hanberg A., Hasegawa R., Kennedy S.W., Kubiak T., Larsen J.C., van Leeuwen F.X., Liem A.K., Nolt C., Peterson R.E., Poellinger L., Safe S., Schrenk D., Tillitt D., Tysklind M., Younes M., Waern F., Zacharewski T. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Environ. Health Perspect. 106:1998;775-792.
8. Whitlock J.P. Jr. Mechanistic aspects of dioxin action. Chem. Res. Toxicol. 6:1993;754-763.
9. Exposure and human health reassessment of 2,3,7,8-tetrachlorodibenzo-p- dioxin (TCDD) and related compounds. Part III. Integrated summary and risk characterization for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. 2000;U.S.Environmental Protection Agency, Washington, DC. SAB review draft EPA/600/P-00/001Bg.
10. Starr T.B. Significant shortcomings of the U.S. Environmental Protection Agency's latest draft risk characterization for dioxin-like compounds. Toxicol. Sci. 64:2001;7-13.
11. Crump K.S., Canady R., Kogevinas M. Meta-analysis of dioxin cancer dose response for three occupational cohorts. Environ. Health Perspect. 111:2003;681-687.
12. Hassoun E.A., Li F., Abushaban A., Stohs S.J. The relative abilities of TCDD and its congeners to induce oxidative stress in the hepatic and brain tissues of rats after subchronic exposure. Toxicology. 145:2000;103-113.
13. Hassoun E.A., Stohs S.J. TCDD, endrin and lindane induced oxidative stress in fetal and placental tissues of C57BL/6J and DBA/2J mice. Comp. Biochem. Physiol. C. 115:1996;11-18.
14. Shertzer H.G., Nebert D.W., Puga A., Ary M., Sonntag D., Dixon K., Robinson L.J., Cianciolo E., Dalton T.P. Dioxin causes a sustained oxidative stress response in the mouse. Biochem. Biophys. Res. Commun. 253:1998;44-48.
15. Slezak B.P., Hatch G.E., DeVito M.J., Diliberto J.J., Slade R., Crissman K., Hassoun E., Birnbaum L.S. Oxidative stress in female B6C3F1 mice following acute and subchronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol. Sci. 54:2000;390-398.
16. Stohs S.J. Oxidative stress induced by 2,3,7,8-tetrachlorodibenzo-p- dioxin (TCDD). Free Radic. Biol. Med. 9:1990;79-90.
17. Yoshida R., Ogawa Y. Oxidative stress induced by 2,3,7,8- tetrachlorodibenzo-p-dioxin: an application of oxidative stress markers to cancer risk assessment of dioxins. Ind. Health. 38:2000;5-14.
18. Park J.-Y., Shigenaga M.K., Ames B.N. Induction of cytochrome P4501A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage. Proc. Natl. Acad. Sci. USA. 93:1996;2322-2327.
19. Puga A., Maier A., Medvedovic M. The transcriptional signature of dioxin in human hepatoma HepG2 cells. Biochem. Pharmacol. 60:2000;1129-1142.
20. Nebert D.W., Roe A.L., Dieter M.Z., Solis W.A., Yang Y., Dalton T.P. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem. Pharmacol. 59:2000;65-85.
21. Dalton T.P., Puga A., Shertzer H.G. Induction of cellular oxidative stress by aryl hydrocarbon receptor activation. Chem.-Biol.Interact. 141:2002;77-95.
22. Cederbaum A.I., Wu D., Mari M., Bai J. CYP2E1-dependent toxicity and oxidative stress in HepG2 cells. Free Radic. Biol. Med. 31:2001;1539-1543.
23. Ekstrom G., Cronholm T., Ingelman-Sundberg M. Hydroxyl-radical production and ethanol oxidation by liver microsomes isolated from ethanol-treated rats. Biochem. J. 233:1986;755-761.
24. Ahmed S.S., Napoli K.L., Strobel H.W. Oxygen radical formation during cytochrome P450-catalyzed cyclosporine metabolism in rat and human liver microsomes at varying hydrogen ion concentrations. Mol. Cell. Biochem. 151:1995;131-140.
25. Puntarulo S., Cederbaum A.I. Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes. Free Radic. Biol. Med. 24:1998;1324-1330.
26. Schlezinger J.J., Stegeman J.J. Induction and suppression of cytochrome P450 1A by 3,3′,4,4′,5-pentachlorobiphenyl and its relationship to oxidative stress in the marine fish scup (Stenotomus chrysops). Aquat. Toxicol. 52:2001;101-115.
27. Schlezinger J.J., White R.D., Stegeman J.J. Oxidative inactivation of cytochrome P-450 1A (CYP1A) stimulated by 3,3′,4,4′- tetrachlorobiphenyl: production of reactive oxygen by vertebrate CYP1As. Mol. Pharmacol. 56:1999;588-597.
28. Diliberto J.J., Akubue P.I., Luebke R.W., Birnbaum L.S. Dose-response relationships of tissue distribution and induction of CYP1A1 and CYP1A2 enzymatic activities following acute exposure to 2,3,7,8,-tetrachlorodibenzo-p- dioxin (TCDD) in mice. Toxicol. Appl. Pharmacol. 130:1995;197-208.
29. Santostefano M.J., Ross D.G., Savas U., Jefcoate C.R., Birnbaum L.S. Differential time-course and dose-response relationships of TCDD-induced CYP1B1, CYP1A1, and CYP1A2 proteins in rats. Biochem. Biophys. Res. Commun. 233:1997;20-24.
30. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34:2002;83-448.
31. Eaton D.L., Gallagher E.P., Bammler T.K., Kunze K.L. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics. 5:1995;259-274.
32. Pelkonen O., Raunio H. Metabolic activation of toxins: tissue-specific expression and metabolism in target organs. Environ. Health Perspect. 105(Suppl 4):1997;767-774.
33. Uno S., Dalton T.P., Shertzer H.G., Genter M.B., Warshawsky D., Talaska G., Nebert D.W. Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyp1a1(-/-) knockout mice having increased hepatic BaP-DNA adduct levels. Biochem. Biophys. Res. Commun. 289:2001;1049-1056.
34. Shertzer H.G., Dalton T.P., Talaska G., Nebert D.W. Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2(-/-) knockout mice. Toxicol. Appl. Pharmacol. 181:2002;32-37.
35. Tsuneoka Y., Dalton T.P., Miller M.L., Clay C.D., Shertzer H.G., Talaska G., Nebert D.W. Liver and urinary bladder toxicity, oxidative stress, and adduct formation induced by 4-aminobiphenyl in Cyp1a2(-/-) and Cyp1a2(+/+) mice. J.Natl.Cancer Inst. 95:2003;1227-1237.
36. Senft A., Dalton T.P., Nebert D.W., Genter M.B., Hutchinson R.J., Shertzer H.G. Dioxin increases reactive oxygen production in mouse liver mitochondria. Toxicol.Appl.Pharmacol. 178:2002;15-21.
37. Senft A.P., Dalton T.P., Nebert D.W., Genter M.B., Puga A., Hutchinson R.J., Kerzee J.K., Uno S., Shertzer H.G. Mitochondrial reactive oxygen production is dependent on the aromatic hydrocarbon receptor. Free Radic. Biol. Med. 33:2002;1268-1278.
38. Dalton T.P., Dieter M.Z., Matlib R.S., Childs N.L., Shertzer H.G., Genter M.B., Nebert D.W. Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. Biochem. Biophys. Res. Commun. 267:2000;184-189.
39. Liang H.-C., Li H., McKinnon R.A., Duffy J.J., Potter S.S., Puga A., Nebert D.W. Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. Proc. Natl. Acad. Sci. USA. 93:1996;1671-1676.
40. Nebert D.W., Dalton T.P., Stuart G.W., Carvan M.J. III "Gene-swap knock-in" cassette in mice to study allelic differences in human genes. Ann. N.Y. Acad. Sci. 919:2000;148-170.
41. Shertzer H.G., Nebert D.W., Senft A.P., Dingeldein M., Genter M.B., Dalton T.P. Spectrophotometric assay for acetanilide 4-hydroxylase, an estimate of CYP1A2 enzyme activity. Toxicol. Methods. 11:2001;81-88.
42. Nebert D.W., Gelboin H.V. Substrate-inducible microsomal aryl hydroxylase in mammalian cell culture: I.Assay and properties of induced enzyme. J. Biol. Chem. 243:1968;6242-6249.
43. Koop D.R. Hydroxylation of p-nitrophenol by rabbit ethanol-inducible cytochrome P-450 isoform 3a. Mol. Pharmacol. 29:1986;399-404.
44. Shertzer H.G., Hall J.E., Seed J.R. Hepatic microsomal alterations during chronic trypanosomiasis in the field vole, Microtus montanus. Mol. Biochem. Parasitol. 6:1982;25-32.
45. Shertzer H.G., Bannenberg G.L., Rundgren M., Moldéus P. Relationship of membrane fluidity, chemoprotection, and the intrinsic toxicity of butylated hydroxytoluene. Biochem. Pharmacol. 42:1991;1587-1593.
46. Shertzer H.G., Låstbom L., Sainsbury M., Moldéus P. Menadione-mediated membrane fluidity alterations and oxidative damage in rat hepatocytes. Biochem. Pharmacol. 43:1992;2135-2142.
47. Gadeholt G. Ethanol-inducible cytochrome P-450 is more susceptible to in vitro carbon tetrachloride-mediated destruction than phenobarbital-inducible and beta-naphthoflavone-inducible cytochromes P-450. Acta Pharmacol. Toxicol. (Copenh). 55:1984;216-223.
48. Moody D.E. The effect of tetrahydrofuran on biological systems: does a hepatotoxic potential exist? Drug Chem. Toxicol. 14:1991;319-342.
49. Eagling V.A., Tjia J.F., Back D.J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 45:1998;107-114.
50. Sai Y., Dai R., Yang T.J., Krausz K.W., Gonzalez F.J., Gelboin H.V., Shou M. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica. 30:2000;327-343.
51. Park J.Y., Harris D. Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. J. Med. Chem. 46:2003;1645-1660.
52. Sesardic D., Boobis A.R., Murray B.P., Murray S., Segura J., de la T.R., Davies D.S. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 29:1990;651-663.
53. Twaroski T.P., O'Brien M.L., Larmonier N., Glauert H.P., Robertson L.W. Polychlorinated biphenyl-induced effects on metabolic enzymes, AP-1 binding, vitamin E, and oxidative stress in the rat liver. Toxicol. Appl. Pharmacol. 171:2001;85-93.
54. Twaroski T.P., O'Brien M.L., Robertson L.W. Effects of selected polychlorinated biphenyl (PCB) congeners on hepatic glutathione, glutathione-related enzymes, and selenium status: implications for oxidative stress. Biochem. Pharmacol. 62:2001;273-281.
55. Diliberto J.J., Burgin D., Birnbaum L.S. Role of CYP1A2 in hepatic sequestration of dioxin: studies using CYP1A2 knock-out mice. Biochem. Biophys. Res. Commun. 236:1997;431-433.
56. Wang X., Santostefano M.J., Evans M.V., Richardson V.M., Diliberto J.J., Birnbaum L.S. Determination of parameters responsible for pharmacokinetic behavior of TCDD in female Sprague-Dawley rats. Toxicol. Appl. Pharmacol. 147:1997;151-168.
57. Wang X., Santostefano M.J., DeVito M.J., Birnbaum L.S. Extrapolation of a PBPK model for dioxins across dosage regimen, gender, strain, and species. Toxicol. Sci. 56:2000;49-60.
58. Toborek M., Barger S.W., Mattson M.P., Espandiari P., Robertson L.W., Hennig B. Exposure to polychlorinated biphenyls causes endothelial cell dysfunction. J. Biochem. Toxicol. 10:1995;219-226.
59. Teraoka H., Dong W., Tsujimoto Y., Iwasa H., Endoh D., Ueno N., Stegeman J.J., Peterson R.E., Hiraga T. Induction of cytochrome P450 1A is required for circulation failure and edema by 2,3,7,8-tetrachlorodibenzo-p-dioxin in zebrafish. Biochem. Biophys. Res. Commun. 304:2003;223-228.
60. Gutteridge J.M. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin. Chem. 41:1995;1819-1828.
61. Jeffcoat R., James A.T. Interrelationship between the dietary regulation of fatty acid synthesis and the fatty acyl-CoA desaturases. Lipids. 12:1977;469-474.
62. Ntambi J.M. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J. Lipid Res. 40:1999;1549-1558.
63. Leikin A.I., Brenner R.R. In vivo cholesterol removal from liver microsomes induces changes in fatty acid desaturase activities. Biochim. Biophys. Acta. 963:1988;311-319.
64. Sen C.K., Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 10:1996;709-720.
65. Tosco A., Gargano S., Kobayashi G.S., Maresca B. An AP1 element is involved in transcriptional regulation of delta9-desaturase gene of Histoplasma capsulatum. Biochem. Biophys. Res. Commun. 230:1997;457-461.
66. Puga A., Barnes S.J., Chang C., Zhu H., Nephew K.P., Khan S.A., Shertzer H.G. Activation of transcription factors activator protein-1 and nuclear factor-κB by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem. Pharmacol. 59:2000;997-1005.
67. Smith A.G., Davies R., Dalton T.P., Miller M.L., Judah D., Riley J., Gant T., Nebert D.W. Intrinsic hepatic phenotype associated with the cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. Environ. Health Perspect. 111:2003;855-861.
68. Ding X., Kaminsky L.S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43:2003;149-173.
69. Dey A., Jones J.E., Nebert D.W. Tissue- and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized in situ hybridization. Biochem. Pharmacol. 58:1999;525-537.
70. Wei C., Caccavale R.J., Kehoe J.J., Thomas P.E., Iba M.M. CYP1A2 is expressed along with CYP1A1 in the human lung. Cancer Lett. 171:2001;113-120.
71. Hukkanen J., Pelkonen O., Hakkola J., Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev. Toxicol. 32:2002;391-411.
72. Finnstrom N., Bjelfman C., Soderstrom T.G., Smith G., Egevad L., Norlen B.J., Wolf C.R., Rane A. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin. Invest. 31:2001;880-886.
73. Iba M.M., Storch A., Ghosal A., Bennett S., Reuhl K.R., Lowndes H.E. Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum. Arch. Toxicol. 77:2003;547-554.
74. Lee S.S., Buters J.T., Pineau T., Fernandez-Salguero P., Gonzalez F.J. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 271:1996;12063-12067.
75. Kono H., Bradford B.U., Yin M., Sulik K.K., Koop D.R., Peters J.M., Gonzalez F.J., McDonald T., Dikalova A., Kadiiska M.B., Mason R.P., Thurman R.G. CYP2E1 is not involved in early alcohol-induced liver injury. Am. J. Physiol. 277:1999;G1259-G1267.
76. Forsberg L., de Faire U., Morgenstern R. Oxidative stress, human genetic variation, and disease. Arch. Biochem. Biophys. 389:2001;84-93.
77. Nebert D.W., McKinnon R.A., Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol. 15:1996;273-280.
78. Nebert D.W., Russell D.W. Clinical importance of the cytochromes P450. Lancet. 360:2002;1155-1162.
79. Butler M.A., Lang N.P., Young J.F., Caporaso N.E., Vineis P., Hayes R.B., Teitel C.H., Massengill J.P., Lawsen M.F., Kadlubar F.F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 2:1992;116-127.
80. Ikeya K., Jaiswal A.K., Owens R.A., Jones J.E., Nebert D.W., Kimura S. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol. Endocrinol. 3:1989;1399-1408.
81. Tang B.K., Zhou Y., Kadar D., Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics. 4:1994;117-124.
82. Guengerich F.P., Kim D.H., Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4:1991;168-179.
83. Howard L.A., Ahluwalia J.S., Lin S.K., Sellers E.M., Tyndale R.F. CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics. 13:2003;321-328.
84. Hu Y., Oscarson M., Johansson I., Yue Q.Y., Dahl M.L., Tabone M., Arinco S., Albano E., Ingelman-Sundberg M. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol. Pharmacol. 51:1997;370-376.
85. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants: the role of the CYP family of enzymes. Mutat. Res. 482:2001;11-19.
86. Meyer U.A. Pharmacogenetics and adverse drug reactions. Lancet. 356:2000;1667-1671.
87. Phillips K.A., Veenstra D.L., Oren E., Lee J.K., Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 286:2001;2270-2279.
88. Maier A., Micka J., Miller K., Denko T., Chang C.Y., Nebert D.W., Puga A. Aromatic hydrocarbon receptor polymorphism: development of new methods to correlate genotype with phenotype. Environ. Health Perspect. 106:1998;421-426.
89. Micka J., Milatovich A., Menon A., Grabowski G.A., Puga A., Nebert D.W. Human Ah receptor (AHR) gene: localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics. 7:1997;95-101.
90. Newcomb M., Hollenberg P.F., Coon M.J. Multiple mechanisms and multiple oxidants in P450-catalyzed hydroxylations. Arch. Biochem. Biophys. 409:2003;72-79.
91. Hamm J.T., Ross D.G., Richardson V.M., Diliberto J.J., Birnbaum L.S. Methoxyresorufin: an inappropriate substrate for CYP1A2 in the mouse. Biochem. Pharmacol. 56:1998;1657-1660.